MIRA Pharmaceuticals (MIRA) Up Over 400% on Positive Preclinical Study Results Related to Ketamine in Treatment of Neurological Disorders
    MIRA Pharmaceuticals (MIRA) Up Over 400% on Positive Preclinical Study Results Related to Ketamine in Treatment of Neurological Disorders
    PRISM Biotech

    July 22, 2024 - by Ashlee Vogenthaler

    MIRA Pharmaceuticals (MIRA) Up Over 400% on Positive Preclinical Study Results Related to Ketamine in Treatment of Neurological Disorders

    22 July 2024

    New York, July 22, 2024 - PRISM MarketView - Today the leading pre-clinical pharmaceutical company, MIRA Pharmaceuticals, Inc. (MIRA) announced new preclinical study results for its novel oral ketamine analog, Ketamir-2 which, is under investigation for its potential in treating neurological and neuropsychiatric disorders, including depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).

    Mira Pharmaceuticals - Prism MarketView

    Mira Pharmaceuticals Developing the next-generation FDA-approved novel synthetic THC analog MIRA1a is being developed to treat anxiety and cognitive decline i

    Read More

    MIRA is in the process of submitting an Investigational New Drug (IND) to the FDA by the end of this year which would grant them the ability to test Ketamir-2 on humans.
    The company previously announced that Ketamir-2’s oral bioavailability is predicted to be around 80%, significantly higher than traditional ketamine’s less than 30%. Preclinical studies have also demonstrated that oral Ketamir-2 is safe at high doses and effective in various anti-depressant and anxiolytic models. Moreover, it does not appear to cause hyper-locomotor activity, a common side effect associated with traditional ketamine.

    “Our findings on Ketamir-2 underline its potential as a groundbreaking treatment for mental health disorders. We are committed to advancing Ketamir-2 towards clinical trials and making this innovative treatment available to patients in need.”

    Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals

    To see this content properly accept cookies.
    MIRA currently leads the PRISM Psychedelics Index and is up over 400% on the day upon the release of this news.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.